MedTrace Logo

Meibomian Gland Dysfunction Management With ZEST Protocol

NCT03968731 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-07-14

No results posted yet for this study

Summary

The purpose of this study is to investigate if cleaning the eyelid margin with the ZEST protocol (Zocular Eyelid System Treatment) in patients intolerant to contact lens wear consequent to Meibomian gland dysfunction (MGD) will improve the MGD and contact lens wear comfort.

Conditions

  • Meibomian Gland Dysfunction
  • Dry Eye Syndromes
  • Ocular Surface Disease

Interventions

OTHER

Zocular Eyelid System Treatment

Zocular products contain okra-infused Zocusome micelles that gently lift and clear the oil, debris, and residue on eyelid margins. THerefore, the ZEST treatment is expected to improve signs and symptoms of Meibomian gland dysfunction (MGD) and reduce Contact lens discomfort associated with MGD.

Sponsors & Collaborators

  • University of the Incarnate Word

    lead OTHER

Principal Investigators

  • Srihari Narayanan, OD, PhD · University of the Incarnate Word

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-10
Primary Completion
2020-03-31
Completion
2020-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03968731 on ClinicalTrials.gov